Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ipsoprubart |
| Synonyms | |
| Therapy Description |
Ipsoprubart (ELA026) is a monoclonal antibody targeting SIRPA/B, which potentially decreases macrophage adhesion (PMID: 41345615). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ipsoprubart | ELA026|ELA-026|ELA 026 | SIRPA Antibody 8 | Ipsoprubart (ELA026) is a monoclonal antibody targeting SIRPA/B, which potentially decreases macrophage adhesion (PMID: 41345615). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07465835 | Phase I | Ipsoprubart | A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) | Recruiting | USA | 0 |